Biophysical Characterization of the Interaction between a Transport Human Plasma Protein and the 5,10,15,20-Tetra(pyridine-4-yl)porphyrin

Otávio Augusto Chaves 1,*, Bernardo A. Iglesias 2 and Carlos Serpa 1,*

1 CQC-IMS, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal
2 Bioinorganic and Porphyrinoids Materials Lab, Department of Chemistry, Federal University of Santa Maria, Santa Maria 97105-900, Brazil
* Correspondence: otavioaugustochaves@gmail.com (O.A.C.); serpasoa@ci.uc.pt (C.S.)

Abstract: The interaction between human serum albumin (HSA) and the non-charged synthetic photosensitizer 5,10,15,20-tetra(pyridine-4-yl)porphyrin (4-TPyP) was evaluated by in vitro assays under physiological conditions using spectroscopic techniques (UV-vis, circular dichroism, steady-state, time-resolved, synchronous, and 3D-fluorescence) combined with in silico calculations by molecular docking. The UV-vis and steady-state fluorescence parameters indicated a ground-state association between HSA and 4-TPyP and the absence of any dynamic fluorescence quenching was confirmed by the same average fluorescence lifetime for HSA without (4.76 ± 0.11 ns) and with 4-TPyP (4.79 ± 0.14 ns). Therefore, the Stern–Volmer quenching (KSV) constant reflects the binding affinity, indicating a moderate interaction (10^4 M⁻¹) being spontaneous (∆G° = -25.0 kJ/mol at 296 K), enthalpically (∆H° = -9.31 ± 1.34 kJ/mol), and entropically (∆S° = 52.9 ± 4.4 J/molK) driven. Binding causes only a very weak perturbation on the secondary structure of albumin. There is just one main binding site in HSA for 4-TPyP (n ≈ 1.0), probably into the subdomain IIA (site I), where the Trp-214 residue can be found. The microenvironment around this fluorophore seems not to be perturbed even with 4-TPyP interacting via hydrogen bonding and van der Waals forces with the amino acid residues in the subdomain IIA.

Keywords: porphyrin; human serum albumin; spectroscopy; molecular docking; chemical-biological interactions

1. Introduction

Human Serum Albumin (HSA) is the most abundant globular protein in the bloodstream (35–50 g/L). It is synthesized in the liver and is responsible for the transport of both endogenous and exogenous compounds, e.g., fatty acids, hormones, metabolites, and commercial drugs to their target [1,2]. For this reason, from a pharmacological point of view, the interaction between HSA and drugs is crucial for a better understanding of both pharmacokinetics and toxicological profiles [3,4]. The structure of HSA has been elucidated by X-ray analysis and was revealed as an ellipsoid with a heart shape consisting of three domains (I, II, and III), and each domain is divided into two subdomains (A and B) [5,6]. Sudlow and coworkers [7] were one of the first researchers to evaluate the specificity of different drugs in binding with albumin and for this reason, the binding sites I and II, located in subdomains IIA and IIIA, respectively, were known as corresponding Sudlow’s sites I and II.

Porphyrin is a class of compounds containing a flat ring of four linked-heterocyclic groups, sometimes with a central metal atom. There are naturally occurring porphyrins, e.g., protoporphyrin IX, chlorophyll, and cobalamin, however, the synthetic ones have attracted attention mainly due to their applicability as photosensitizers in antimicrobial photodynamic therapy (aPDT) or photodynamic therapy (PDT) of malignant tissues [8,9].
In this sense, 5,10,15,20-tetra(pyridine-4-yl)porphyrin (4-TPyP, Figure 1), a simple non-charged synthetic porphyrin, has attracted attention in the design of novel photosensitizers to PDT, mainly due to its high singlet oxygen quantum yield (Φ<sub>Δ</sub> = 0.76, in acetonitrile) and phototoxicity in a nanomolar scale under green light irradiation (522 nm) with very low light dose (1.0 J/cm<sup>2</sup>) [10]. Recently, binding studies between Bovine Serum Albumin (BSA, a very similar protein compared with HSA, sharing 76% identity and 88% similarity in protein sequence, however, with two tryptophan residues) and 5-phenyl-10,15,20-tri(pyridine-4-yl)porphyrin, a non-charged synthetic porphyrin with structural similarities with 4-TPyP was reported, revealing that the main fluorescence quenching mechanism is static, with binding spontaneous, strong, controlled by electrostatic forces, and the hydrophobicity of the microenvironment around tyrosine (Tyr) and tryptophan (Trp) residues are enhanced in the presence of this porphyrin [11].

![Figure 1. Chemical structure for 5,10,15,20-tetra(pyridine-4-yl)porphyrin.](image)

Since there are not any biophysical reports on the binding capacity of HSA and 4-TPyP (a relevant porphyrin to develop potential leads for PDT), the present study reports this interaction by multiple spectroscopic techniques (UV-vis, circular dichroism, steady-state, time-resolved, synchronous, and 3D-fluorescence) under physiological conditions at pH = 7.4. To offer a molecular-level explanation of the binding HSA:4-TPyP, molecular docking calculations were also carried out for the three main binding sites of albumin (subdomains IIA, IIIA, and IB).

2. Results

2.1. Experimental Binding Capacity of 4-TPyP to HSA

Absorption spectroscopy is a simple technique to preliminary evaluate qualitatively the binding capacity between HSA and 4-TPyP. From Figure 2A, was noticed that the HSA solution presents two absorption maximums: one at 222 nm due to the π → π<sup>*</sup> transition of C=O (from amide group) and the other at 280 nm attributed to n → π<sup>*</sup> transition which is associated with the aromatic amino acid residues tryptophan (Trp), phenylalanine (Phe), and tyrosine (Tyr) [3,12]. On the other hand, the absorption peaks at wavelengths higher than 400 nm is only attributed to the electronic transitions of 4-TPyP (Soret and Q-bands) [10]. Upon the addition of 4-TPyP in the albumin solution, there is a significant hyperchromic effect in the 250–300 nm range (red line in Figure 2A), however, to assess if the observed hyperchromic displacement is in fact a consequence of the HSA:4-TPyP interaction, and not simply a contribution from porphyrin absorption, the HSA:4-TPyP and 4-TPyP absorption spectra were subtracted. The resulting spectrum in the 250–300 nm range (blue line in Figure 2A) continues to present a hyperchromic effect with a small blue-shift, indicating a ground-state association at this concentration [3,12–14]. This phenomenon may be confirmed by the hypochromic effect in the Soret Band (≈400 nm) of 4-TPyP in the presence of HSA. Additionally, there was also evidence of a hyperchromic effect in the 200–250 nm range upon addition of 4-TPyP into the HSA solution, however, after the 4-TPyP absorption spectrum subtraction, this effect was due to the contribution of absorption from 4-TPyP, being the correct effect for this wavelength range as a hypochromic effect that
might be considered as preliminary evidence that 4-TPyP can cause some perturbation on the albumin structure [12,15].

Steady-state fluorescence spectroscopy is a more sensitive technique than UV-vis absorption to study the binding capacity of different small compounds with proteins, including porphyrin binding with HSA [14]. Figure 2B depicts the steady-state fluorescence emission of HSA without and upon successive additions of 4-TPyP at 310 K (λ_{exc} = 280 nm). (C) Stern–Volmer plots for the interaction HSA:4-TPyP corresponding to the steady-state fluorescence data at three different temperatures. (D) Van’t Hoff plot based on $K_{SV}$ values for HSA:4-TPyP. (E) Double logarithmic plots for the interaction HSA:4-TPyP at three different temperatures. The $r^2$ in each plot is the coefficient of determination. [HSA] = 1.0 × 10^{-5} M and [4-TPyP] = 0.17, 0.33, 0.50, 0.66, 0.83, 0.99, 1.15, and 1.32 × 10^{-5} M.

Table 1 summarizes the binding parameters obtained by steady-state fluorescence data (Figure 2C–E). The Stern–Volmer quenching ($K_{SV}$) constant values decrease with increasing
temperature and the bimolecular quenching rate \( (k_q) \) constant values are \( 10^{12} \text{ M}^{-1} \text{s}^{-1} \), being three orders of magnitude larger than the maximum diffusion rate constant in water \( (k_{\text{diff}} \approx 7.40 \times 10^9 \text{ M}^{-1} \text{s}^{-1}) \) at 298 K, according to the Smoluchowski–Stokes–Einstein theory at 298 K [17], indicating a ground-state association between HSA and 4-TPyP (static quenching mechanism) [15], agreeing with UV-vis results.

**Table 1.** Binding parameters for the interaction HSA:4-TPyP in PBS (pH = 7.4) at three different temperatures.

| T (K) | \( K_{SV} \times 10^4 \) (M\(^{-1}\)) \^[a] | \( k_q \times 10^{12} \) (M\(^{-1}\)s\(^{-1}\)) \^[a] | \( n \) \^[b] | \( \Delta H^\circ \) (kJ/mol) \^[c] | \( \Delta S^\circ \) (J/(molK)) \^[c] | \( \Delta G^\circ \) (kJ/mol) |
|-------|---------------------------------|---------------------------------|--------|-----------------|-----------------|-----------------|
| 296   | 2.57 ± 0.05                    | 5.39 ± 0.11                    | 0.857 ± 0.022 | -9.31 ± 1.34   | 52.9 ± 4.4      | -25.0           |
| 303   | 2.30 ± 0.03                    | 4.84 ± 0.06                    | 0.948 ± 0.016 | -9.31 ± 1.34   | 52.9 ± 4.4      | -25.3           |
| 310   | 2.17 ± 0.07                    | 4.55 ± 0.14                    | 1.15 ± 0.04   | -9.31 ± 1.34   | 52.9 ± 4.4      | -25.7           |

\^[a] Corresponding to Stern–Volmer plots. \^[b] Corresponding to double-logarithmic plots. \^[c] Corresponding to van’t Hoff plot.

To further confirm the main fluorescence quenching mechanism detected by both UV-vis analysis and Stern–Volmer approximation, time-resolved fluorescence decays were obtained without and with the maximum porphyrin concentration used in the UV-vis absorption and steady-state fluorescence (Figure 3). The HSA decay without porphyrin showed two fluorescence lifetimes: \( \tau_1 = 1.67 \pm 0.13 \) ns and \( \tau_2 = 5.67 \pm 0.11 \) ns, with relative percentage of 22.7% and 77.3%, respectively, agreeing with the literature [18,19], while the complex HSA:4-TPyP showed \( \tau_1 = 1.80 \pm 0.19 \) ns and \( \tau_2 = 5.52 \pm 0.13 \) ns, with a relative percentage of 19.7% and 80.3%, respectively. Amiri and coworkers [20] observed that the fluorescence decay for emissive amino acid Trp in HSA yields three lifetimes. The first two lifetimes are already observed for free-Trp (attributed to excited-state Trp structures) and the third, longer one, results from interactions between the Trp residue and its microenvironment in the protein matrix. The first lifetime is short (sub nanosecond) with a low pre-exponential factor (3%). Thus, due to the instrumental limitations, most reports (as we in the present work) observe solely two lifetimes. Values of the two fluorescence lifetimes and of their pre-exponentials (this is, the relative population of the Trp excited states which are the origin of the fluorescence) may depend on the microenvironment and on the extension and nature of interactions formed upon HAS: ligand complex formation. The measured lifetimes values and the respective percentages do not vary significantly with the formation of the complex, evidence that the microenvironment around the fluorophore is not perturbed very much with the presence of 4-TPyP.

Since the average fluorescence lifetime of HSA without (4.76 ± 0.11 ns) and with 4-TPyP (4.79 ± 0.14 ns) is the same inside the experimental error, time-resolved fluorescence analysis indicates the absence of dynamic quenching mechanisms and confirmed the ground-state association between HSA and 4-TPyP [15,21]. Therefore, the \( K_{SV} \) values can also estimate the binding affinity [15,22], being in the order of \( 10^4 \text{ M}^{-1} \). For this reason, the double-logarithmic approximation was applied only to determine the number of binding sites \( (n) \) in the range of 0.857–1.15, which indicates an interaction in the proportion 1:1—one single albumin molecule binds with one molecule of 4-TPyP [23].

The negative \( \Delta G^\circ \) values are consistent with the spontaneity of the binding process in all the evaluated temperatures and since \( \Delta H^\circ \) and \( \Delta S^\circ \) values are negative and positive, respectively, the association HSA:4-TPyP is enthalpically and entropically driven [24].
Comparing the steady-state fluorescence technique with the synchronous fluorescence approach to detect possible perturbations in the microenvironment around the two main fluorophores of albumin (Tyr and Trp residues) after drug binding [25–27]. Figure 4 shows the SF spectra for HSA without and upon successive additions of 4-TPyP at Δλ 15 and 60 nm for Tyr and Trp residues, respectively. For both Δλ, there is a significant decrease in the fluorescence signal upon additions of porphyrin, however, it did not induce any blue- or red-shift, agreeing with steady-state fluorescence data (Figure 2B), which indicated that the binding of 4-TPyP does not induce any significant perturbation on the microenvironment around the fluorophores.

Circular dichroism (CD) plays an essential role in studying perturbation on the secondary structure of albumin upon drug binding [28,29]. Figure 5A depicts the CD spectra for HSA without and with 4-TPyP, while Figure 5B shows the corresponding secondary structure content. The CD spectra of HSA and HSA:4-TPyP are practically similar in shape and peak position: two minimum peaks, one at 208 nm and the other at 222 nm. Addition-
Finally, the 3D-fluorescence spectroscopy was applied as additional and conclusive evidence for the experimental data obtained by steady-state fluorescence, SF, and CD spectra [30]. Figure 6 depicts the 3D-fluorescence spectra of HSA and HSA:4-TPyP and their corresponding contour maps, while Table 2 summarizes the fluorescence characteristics of these spectra. Peaks I ($\lambda_{ex} = 280$ nm) and II ($\lambda_{ex} = 225$ nm) are characteristics of the intrinsic fluorescence spectral behavior of HSA, mainly due to the absorption of the fluorophores Tyr and Trp, however, the peaks “a” ($2\lambda_{ex} = \lambda_{em}$) and “b” ($2\lambda_{ex} = \lambda_{em}$) are characteristics of Rayleigh and second-order scattering, respectively [31,32]. The presence of 4-TPyP in the HSA solution did not cause a significant Stokes shift in the position of peaks I and II, as well as the fluorescence intensity was reduced by 10.8% and 16.6% for peaks I and II, respectively, reinforcing the data obtained by the other spectroscopic techniques. It is important to highlight that in this technique, the scattering peaks are so high probably due to the aggregation of 4-TPyP in the PBS medium, indicating that despite the presence of HSA, the non-charged porphyrin 4-TPyP still can form some aggregate.

| System         | Peak | Peak Position ($\lambda_{ex}$/$\lambda_{em}$ nm/nm) | Intensity $\times 10^3$ (a.u.) |
|----------------|------|----------------------------------------------------|-------------------------------|
| HSA            | a    | 225/225 $\rightarrow$ 355/355                      | 4.00 $\rightarrow$ 1.89        |
|                | b    | 230/460                                            | 2.01                          |
|                | I    | 280/335                                            | 2.13                          |
|                | II   | 225/330                                            | 3.56                          |
| HSA:4-TPyP     | a    | 225/225 $\rightarrow$ 355/355                      | 3.16 $\rightarrow$ 1.66        |
|                | b    | 230/460                                            | 1.66                          |
|                | I    | 280/340                                            | 1.90                          |
|                | II   | 225/335                                            | 2.97                          |

Table 2. The 3D-fluorescence spectral characteristics for HSA and HSA:4-TPyP in pH = 7.4 at room temperature.
The 3D structure of HSA has three main binding sites with different specificities: site I, also known as Sudlow’s site I, located in the subdomain IIA, site II, also known as Sudlow’s site II, located in the subdomain IIIA, and site III located in the subdomain IB [6,33,34]. To suggest the main binding site and to offer a molecular-level explanation of the binding capacity of 4-TPyP to HSA, molecular docking calculations were carried out. The docking score value (dimensionless) for sites I and III was 51.5 and 45.7, respectively, while 4-TPyP did not have any favorable pose for site II. Figures 7A and 7B depict the superposition of 4-TPyP and the amino acid residues into subdomain IIA.

2.3. Molecular-Level Explanation on the Binding Capacity of 4-TPyP to HSA

The 3D structure of HSA has three main binding sites with different specificities: site I, also known as Sudlow’s site I, located in the subdomain IIA, site II, also known as Sudlow’s site II, located in the subdomain IIIA, and site III located in the subdomain IB [6,33,34]. To suggest the main binding site and to offer a molecular-level explanation of the binding capacity of 4-TPyP to HSA, molecular docking calculations were carried out. The docking score value (dimensionless) for sites I and III was 51.5 and 45.7, respectively, while 4-TPyP did not have any favorable pose for site II. Figure 7A,B depict the superposition of the binding pose of 4-TPyP into subdomains IIA and IB in a cartoon and electrostatic representation, respectively. The 4-TPyP interacts preferentially in a positive electron density pocket being stabilized mainly by hydrogen bonding and van der Waals forces with the pyridyl moiety of 4-TPyP structure within a distance of 3.10, 2.90, 3.70, and 3.20 Å, respectively. On the other hand, the hydrogen atom from the polar group of Lys-195, Arg-218, and Asn-295 is potential donor for hydrogen bonding with 4-TPyP within a distance of 3.40, 3.40, and 3.30 Å, respectively. Finally, molecular docking calculations did not suggest any π-π, π-alkyl, or non-conventional hydrogen bonding interactions between 4-TPyP and the amino acid residues into subdomain IIA.

Figure 6. The 3D-fluorescence spectra and the corresponding contour maps for (A,A') HSA and (B,B') HSA:4-TPyP in pH = 7.4 at room temperature. [HSA] = 1.0 × 10⁻⁶ M and [4-TPyP] = 1.32 × 10⁻⁶ M.
and 3.20 Å, respectively. On the other hand, the hydrogen atom from the polar group of Lys-195, Arg-218, and Asn-295 is a potential donor for hydrogen bonding with 4-TPyP within a distance of 3.40, 3.40, and 3.30 Å, respectively, while the negative charged carboxyl group of Glu-292 is a potential acceptor for hydrogen bonding with the amino group of the tetrapyrrolic core from 4-TPyP structure within a distance of 3.40 Å. Finally, molecular docking calculations did not suggest any π-π, π-alkyl, or non-conventional hydrogen bonding interactions between 4-TPyP and the amino acid residues into subdomain IIA.

Figure 7. Superposition of molecular docking results for the interaction HSA:4-TPyP into subdomains IIA and IB (sites I and III, respectively) in terms of (A) cartoon representation and (B) electrostatic potential map for albumin (blue and red for positive and negative electrostatic density, respectively). (C) The main amino acid residues that interact with 4-TPyP into site I. Selected amino acid residues and 4-TPyP are represented as sticks in cyan and pink, respectively. Elements’ color: hydrogen, nitrogen, and oxygen in white, dark blue, and red, respectively.

Table 3. The main amino acid residues and interactive forces for HSA:4-TPyP in the site I.

| Amino Acid Residue | Interaction            | Distance (Å) |
|--------------------|------------------------|--------------|
| Lys-195            | Hydrogen bonding       | 3.40         |
| Trp-214            | Van der Waals          | 3.50         |
| Arg-218            | Hydrogen bonding       | 3.40         |
| His-288            | Van der Waals          | 3.10         |
| Glu-292            | Hydrogen bonding       | 3.40         |
| Asn-295            | Hydrogen bonding       | 3.30         |
| Lys-444            | Van der Waals          | 2.90         |
| Pro-447            | Van der Waals          | 3.70         |
| Val-455            | Van der Waals          | 3.20         |

3. Discussion

The interaction between non-charged or charged porphyrins to albumin has been widely reported as a hot topic by different researchers, however, these studies do not apply the same mathematical approximations and/or methodologies among them [11,14,22,34–40], making a direct comparison with our data difficult. In this sense, for a better interpre-
tation of the binding capacity between HSA and 4-TPyP, reports were selected for porphyrins with both similar structure and experimental/mathematical approaches, more specifically with a non-charged porphyrin (5-phenyl-10,15,20-tri(pyridine-4-yl)-porphyrin, TriPyP) [11] and charged positively porphyrins 5,10,15,20-tetrakis(4-benzylpyridinium-4-yl)porphyrin (TBzPyP) [14], 5,10,15,20-tetrakis(1-[Ru(bpy)$_2$Cl]_pyridinium-4-yl)porphyrin (4-RuTPyP) [38], 5,10,15,20-tetrakis(1-methyl-pyridinium-4-porphyrin (4-TMPyP), and 5,10,15,20-tetrakis(1-[Pt(bpy)Cl]_pyridinium-4-yl)porphyrin (4-PtTPyP) [22].

The preliminary binding evaluation was carried out by UV-vis absorption technique, demonstrating hypochromic and hyperchromic effects in the 200–250 and 250–300 nm range, respectively, after the subtraction of the 4-TPyP absorption signal in the UV-vis absorption spectrum of HSA:4-TPyP, indicating that 4-TPyP can cause some perturbation on the albumin structure (analysis in the 200–250 nm range) and there is a ground-state association for HSA:4-TPyP (analysis in the 250–300 nm range) [12,13]. Unfortunately, we did not find any reports for the binding albumin:porphyrin under the same UV-vis approach that we conducted (subtraction of porphyrin absorption signal in the UV-vis absorption profile of albumin:porphyrin) to compare our data with similar porphyrin structures.

The binding of 4-TPyP to HSA does not cause any shift in the maximum fluorescence peak of albumin by both steady-state, synchronous, and 3D-fluorescence techniques, being a clear indication that the evaluated non-charged porphyrin does not perturb the microenvironment around the main fluorophores (Trp, Tyr, and Phe), having the same trend compared to TriPyP [11] and 4-TMPyP [22], however, a different trend considering 4-PtTPyP [22] and 4-RuTPyP [38], indicating that the positive charge in porphyrin structure is not a crucial step in perturbing the microenvironment around the fluorophores, but there is a significant dependence of the steric volume of the groups covalently connected with pyridyl moiety.

The ground-state association for HSA:4-TPyP previously detected by UV-vis analysis was reinforced by both steady-state and time-resolved fluorescence data, showing that the fluorescence quenching mechanism of HSA by 4-TPyP is purely static. Therefore, the double-logarithmic approximation to obtain the $K_a$ values ($0.0405$, $0.101$, and $1.19 \times 10^5$ M$^{-1}$ at 296, 303, and 310 K, respectively) is not the best mathematical treatment to estimate the binding affinity of HSA:4-TPyP, reinforcing that in this case, the $K_{SV}$ values besides evaluating the quenching mechanism also determine the binding affinity [15]. As a drug carrier, HSA may aid in the selective delivery of porphyrins to a tumor region and facilitate drug access into the cell via receptor mechanisms (moderate binding affinity for HSA). On the other hand, the same carrier may cause a decrease in the amount of porphyrin available for PDT by its rapid removal from circulation (strong or weak binding affinity for HSA) [37,41]. Since the $K_{SV}$ values are in the order of $10^4$ M$^{-1}$, 4-TPyP binds moderately with albumin, which is favorable to achieving the ideal pharmacokinetic profile for PDT. The same trend was identified in 4-TMPyP and 4-RuTPyP [22], while the porphyrins TBzPyP [14], TriPyP [11], and 4-RuTPyP [38] bind stronger with albumin, indicating that there is not necessarily a charge or steric volume dependence on the binding affinity of pyridyl-porphyrins to albumin but there is a crucial dependence on the nature of the chemical group connected covalently with pyridyl moiety.

In all evaluated temperatures, negative $\Delta G^\circ$ values were obtained, which are consistent with the spontaneity of the binding HSA:4-TPyP and since there are negative and positive values for $\Delta H^\circ$ and $\Delta S^\circ$, respectively, both thermodynamics parameters contribute to the negative $\Delta G^\circ$ value, therefore, the association HSA:4-TPyP is considered enthalpically and entropically driven. According to Ross and Subramanian [42] $\Delta H^\circ < 0$ and $\Delta S^\circ > 0$, indicate that electrostatic forces might contribute significantly to the complex stability, agreeing with in silico data which detected that besides hydrogen bonding, the electrostatic van der Waals interactions play a key intermolecular force for the interaction HSA:4-TPyP into subdomain IIA (site I). Additionally, $\Delta S^\circ > 0$ can also be correlated with the hydrophobic effect governed by desolvation factors upon binding of 4-TPyP into HSA [43]. Interestingly, these results are opposite from those reported for the charged porphyrins 4-RuTPyP [38], 4-

\[ Molecules 2022, 27, 5341 \]
TMPyP, and 4-PtTPyP [22] that identified subdomain IB (site III) as the main binding region, possibly due to the negative electrostatic potential surface of subdomain IB. Unfortunately, there are no in silico or experimental data to identify the main binding site of TBzPyP [14] and TriPyP [11], however, the thermodynamics parameters of TriPyP [11] are like those obtained of 4-TPyP, indicating that the non-charged pyridyl-porphyrins derivatives might interact by the same types of intermolecular forces.

4. Materials and Methods

4.1. Chemicals and Instruments

Commercially available phosphate buffer solution (PBS) and HSA (lyophilized powder, fatty acid-free, globulin free with purity higher than 99%, code A3782-1G) were obtained from Sigma-Aldrich/Merck (St. Louis, MO, USA). One tablet of PBS dissolved in 200 mL of millipore water yields a 0.01 M, 0.0027 M, and 0.137 M of phosphate buffer, potassium chloride, and sodium chloride, respectively, with pH 7.4 at 298 k. Water used in all experiments was Millipore water. Acetonitrile (spectroscopic grade) was obtained from Vetec (Rio de Janeiro, Brazil). The porphyrin 4-TPyP was purchased from PorphyChem (Dijon, France) and a stock solution was prepared in acetonitrile. To increase the solubility of porphyrin in the stock solution the mixture was heated to 323 K and inserted into a home-built ultrasound system. The chemical stability of 4-TPyP under this condition was determined following its corresponding UV-vis profile [10].

The UV-vis, steady-state fluorescence, and circular dichroism (CD) spectra were measured on a Jasco model J-815 optical spectrometer (Easton, MD, USA) and a thermostatic cuvette holder Jasco PFD-425S15F (Easton, MD, USA) was applied to control the temperature in the quartz cell (1.00 cm optical path). All spectra were obtained as the average of three scans with appropriate background corrections. Time-resolved fluorescence measurements were performed on an Edinburgh Instruments fluorimeter model FL920 CD (Edinburgh, UK), equipped with an EPL with excitation wavelength of 280 ± 10 nm, pulse width of 850 ps, and a typical average power of 1.8 µW/pulse, monitoring emission at 340 nm. Synchronous fluorescence (SF) and 3D-fluorescence spectra were performed by the Edinburgh Instruments fluorimeter model Xe900 (Edinburgh, UK).

4.2. Spectroscopic Measurements

The UV-vis spectra were obtained in three different conditions in a quartz cell with 1.00 cm optical path: HSA solution (1.0 × 10−5 M in PBS), 4-TPyP solution (1.32 × 10−5 M in PBS), and HSA:4-TPyP mixture at 310 K in the 200-600 nm range.

The steady-state fluorescence measurements in the 290-450 nm range (λ_{exc} = 280 nm, was used the excitation wavelength of 280 nm instead of 295 nm due to the highest absorption contribution of albumin than porphyrin to minimize the inner filter effect) were carried out for 3.0 mL of HSA solution (1.0 × 10−5 M, in PBS), without and with 4-TPyP (added manually by a micro syringe to achieve final concentrations of 0.17, 0.33, 0.50, 0.66, 0.83, 0.99, 1.15, and 1.32 × 10−5 M) at 296, 303, and 310 K. The maximum concentration of 4-TPyP used in the binding assays corresponds to a stock aliquot of 40 µL of acetonitrile that does not perturb both protein structure and spectroscopic signal [38]. To compensate for the inner filter effect, the maximum steady-state fluorescence intensity values for the system HSA:4-TPyP were corrected by the absorption of porphyrin at excitation (λ = 280 nm) and emission wavelengths (λ = 340 nm), applying Equation (1) [43,44]:

\[ F_{cor} = F_{obs} 10^{\frac{(A_{ex} + A_{em})}{\varepsilon}} \]

where \( F_{cor} \) and \( F_{obs} \) are the corrected and observed steady-state fluorescence intensity values, respectively, while \( A_{ex} \) and \( A_{em} \) are the absorption value at the excitation (λ = 280 nm, \( \varepsilon = 7537.3 \) M\(^{-1}\)cm\(^{-1}\)) and maximum fluorescence emission (λ = 340 nm, \( \varepsilon = 12,659.3 \) M\(^{-1}\)cm\(^{-1}\)) wavelengths, respectively.
To obtain quantitative parameters on the binding capacity of HSA:4-TPyP, the maximum fluorescence data after inner filter correction were treated by Stern–Volmer (Equation (2)), double-logarithmic (Equation (3)), van’t Hoff (Equation (4)), and Gibbs’ free energy (Equation (5)) approximations [15,45–47].

\[
\frac{F_0}{F} = 1 + k_q \tau_0 [Q] = 1 + K_{SV}[Q] \tag{2}
\]

\[
\log \left( \frac{F_0 - F}{F} \right) = n \log [Q] + \log K_a \tag{3}
\]

\[
\ln K_{SV} = -\frac{\Delta H^\circ}{RT} + \frac{\Delta S^\circ}{R} \tag{4}
\]

\[
\Delta G^\circ = \Delta H^\circ - T\Delta S^\circ \tag{5}
\]

where \( F_0 \) and \( F \) are the steady-state fluorescence intensities of HSA without and with 4-TPyP, respectively. The \([Q], K_{SV}, \) and \( k_q \) are the porphyrin concentration, Stern–Volmer quenching constant, and bimolecular quenching rate constant, respectively. The \( \tau_0 \) is the obtained experimental average fluorescence lifetime for HSA without 4-TPyP in PBS (\( \tau_0 = 4.76 \pm 0.11 \) ns), while \( K_a \) and \( n \) are the binding constant and number of binding sites, respectively. The \( \Delta H^\circ, \Delta S^\circ, \) and \( \Delta G^\circ \) are the enthalpy, entropy, and Gibbs’ free energy change, respectively. Finally, \( T \) and \( R \) are the temperature (296, 303, and 310 K) and gas constant (8.3145 J mol\(^{-1}\) K\(^{-1}\)), respectively.

Time-resolved fluorescence decays were obtained for 3.0 mL of HSA solution (1.0 \( \times \) \( 10^{-5} \) M, in PBS) without and with 4-TPyP (1.32 \( \times \) \( 10^{-5} \) M) at room temperature. The instrumental response function (IRF) was collected using a Ludox\textsuperscript{®} dispersion.

The SF spectra were obtained for 3.0 mL of has solution (1.0 \( \times \) \( 10^{-5} \) M, in PBS) without and upon successive additions of 4-TPyP in the same concentrations of porphyrin used in the steady-state fluorescence studies (0.17, 0.33, 0.50, 0.66, 0.83, 0.99, 1.15, and 1.32 \( \times \) \( 10^{-5} \) M) at room temperature in the range of 260-320 nm for Tyr (\( \Delta \lambda = 15 \) nm) and 240-320 nm for Trp (\( \Delta \lambda = 60 \) nm). Finally, the 3D-fluorescence spectra were recorded at the 240–320 nm range for 3.0 mL of HSA solution (1.0 \( \times \) \( 10^{-6} \) M, in PBS) without and upon addition of 4-TPyP (1.32 \( \times \) \( 10^{-6} \) M) using \( \lambda_{exc} = 200–360 \) nm and \( \lambda_{em} = 200–460 \) nm, at room temperature.

The CD spectra (200–260 nm) were recorded for HSA without and with 4-TPyP in PBS at 310 K. The HSA concentration was fixed at 1.0 \( \times \) \( 10^{-6} \) M and porphyrin concentration was those to achieve proportion HSA:4-TPyP of 1:13. The average spectra were obtained from three successive runs and corrected by subtraction of the buffer signal. The CD raw data in ellipticity (\( \Theta_{obs} \), in millidegrees) were normalized and expressed as the mean residue weight (\( \Theta_{MRW} \)) in deg. cm\(^2\)-dmol\(^{-1}\), defined as \( \Theta_{MRW} = (\Theta_{obs} \times 10^{-3}) \times 100 \times MW/(l \times c \times NAA) \), where \( MW \) is the protein molecular weight, \( c \) is the protein concentration in milligrams per milliliter, \( l \) is the light path length in centimeters, and \( NAA \) is the number of amino acids per protein. The secondary structure content was estimated by analysis of the CD spectra using the online server BestSel (Beta Structure Selection http://bestsel.elte.hu/index.php (accessed on 2 June 2022)).

### 4.3. Molecular Docking Procedure

The 4-TPyP structure was built and energy-minimized by the Density Functional Theory (DFT) method with the potential B3LYP and basis set 6-31G*, available in the Spartan’14 software (Wavefunction, Inc., Irvine, USA). The crystallographic structure of HSA was obtained in the Protein Data Bank (PDB), with access code 3JRY [48]. Molecular docking calculations were performed with GOLD 2020.2 software (CCDC, Cambridge Crystallographic Data Centre, Cambridge, UK).

Hydrogen atoms were added to HSA according to the data inferred by GOLD 2020.2. The 4-TPyP structure was built and energy-minimized by the Density Functional Theory (DFT) method with the potential B3LYP and basis set 6-31G*, available in the Spartan’14 software (Wavefunction, Inc., Irvine, USA). The crystallographic structure of HSA was obtained in the Protein Data Bank (PDB), with access code 3JRY [48]. Molecular docking calculations were performed with GOLD 2020.2 software (CCDC, Cambridge Crystallographic Data Centre, Cambridge, UK).

The docking calculation cavity in the protein was established with 8 Å radius from the amino acid residues Trp-214, Tyr-411,
and Tyr-161 for sites I, II, and III, respectively. The number of genetic operations (crossover, migration, mutation) in each docking run was set to 100,000. The scoring function used was ‘ChemPLP’, which is the default function of GOLD 2020.2 software. Figures for the docking poses were generated using PyMOL Delano Scientific LLC software (Schrödinger, New York, NY, USA).

**Author Contributions:** Conceptualization, O.A.C., B.A.I. and C.S.; methodology, O.A.C. and C.S.; software, O.A.C.; validation, O.A.C., B.A.I. and C.S.; formal analysis, O.A.C. and C.S.; investigation, O.A.C.; resources, B.A.I. and C.S.; data curation, O.A.C. and C.S.; writing—original draft preparation, O.A.C.; writing—review and editing, O.A.C., B.A.I. and C.S.; visualization, O.A.C. and C.S.; supervision, B.A.I. and C.S.; project administration, B.A.I. and C.S.; funding acquisition, B.A.I. and C.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was financed by national funds through FCT—Fundação para a Ciência e a Tecnologia, I.P. (Portugal), under the project UIDB/00313/2020.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All analyzed data are contained in the main text of the article. Raw data are available from the authors upon request.

**Acknowledgments:** The authors acknowledge Nanci Camara de Lucas Garden from Chemistry Institute at Federal University of Rio de Janeiro (UFRJ, Brazil) for the time-resolved, synchronous, and 3D-fluorescence facilities. O.A. Chaves thanks Fundação para a Ciência e a Tecnologia (FCT, Portugal) for his PhD fellowship 2020.07504.BD. B.A. Iglesias also thanks Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil, 409.150/2018-5 and 304.711/2018-7), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES-Brazil, finance code 001), and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS-Brazil, PQ Gaucho-21/2551-0002114-4) for the grants.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

**Sample Availability:** Not applicable.

**References**

1. Lee, P.; Wu, X. Review: Modifications of human serum albumin and their binding effect. *Curr. Pharm. Des.* **2015**, *21*, 1862–1865. [CrossRef]
2. Merlot, A.M.; Kalinowski, D.S.; Richardson, D.R. Unraveling the mysteries of serum albumin—More than just a serum protein. *Front. Physiol.* **2014**, *5*, 299. [CrossRef] [PubMed]
3. Chen, B.; Luo, H.; Chen, W.; Huang, Q.; Zheng, K.; Xu, D.; Li, S.; Liu, A.; Huang, L.; Zheng, Y.; et al. Pharmacokinetics, tissue distribution, and human serum albumin binding properties of delicaflavone, a novel anti-tumor candidate. *Front. Pharmacol.* **2021**, *12*, 761884. [CrossRef] [PubMed]
4. Zhivkova, Z.D. Studies on drug-human serum albumin binding: The current state of the matter. *Curr. Pharm. Des.* **2015**, *21*, 1817–1830. [CrossRef] [PubMed]
5. Carter, D.C.; Ho, J.X. Structure of serum albumin. *Adv. Protein Chem.* **1994**, *45*, 153–203.
6. Wardell, M.; Wang, Z.; Ho, J.X.; Robert, J.; Ruker, F.; Ruble, J.; Carter, D.C. The atomic structure of human methemalbumin at 1.9 Å. *Biochem. Biophys. Res. Commun.* **2002**, *291*, 913–918. [CrossRef]
7. Sudlow, G.; Birkett, D.J.; Wade, D.N. Further characterization of specific drug binding sites on human serum albumin. *Mol. Pharmacol.* **1976**, *12*, 1052–1061.
8. Kou, J.; Dou, D.; Yang, L. Porphyrin photosensitizers in photodynamic therapy and its applications. *Oncotarget* **2017**, *8*, 81591–81603. [CrossRef] [PubMed]
9. Amos-Tautua, B.M.; Songca, S.P.; Oluwafemi, O.S. Application of porphyrins in antibacterial photodynamic therapy. *Molecules* **2019**, *24*, 2456. [CrossRef]
10. Tasso, T.T.; Tsubone, T.M.; Baptista, M.S.; MattiazzI, L.M.; Acunha, T.V.; Iglesias, B.A. Isomeric effect on the properties of tetraplatinated porphyrins showing optimized phototoxicity for photodynamic therapy. *Dalton Trans.* **2017**, *46*, 11037–11045. [CrossRef]
11. Chen, X.; Cai, Y.; Zhao, Y.; Ma, H.; Wu, D.; Du, B.; Wei, Q. Quenching and binding mechanism of the intrinsic fluorescence of bovine serum albumin by 5-phenyl-10,15,20-tri-(4-pyridyl)-porphyrin. *J. Porphyr. Phthalocyanines* **2009**, *13*, 933–938. [CrossRef]
36. Yang, L.; Ji, Z.; Peng, Z.; Cheng, G. A novel low symmetry sulfur containing porphyrazine: Synthesis and its interaction with human serum albumin. J. Porphyr. Phthalocyanines 2002, 6, 225–232. [CrossRef]

25. Karthiga, D.; Chandrasekaran, N.; Mukherjee, N. Spectroscopic studies on the interactions of bovine serum albumin in presence of silver nanorod. J. Mol. Liq. 2017, 232, 251–257. [CrossRef]

17. Montalti, M.; Credi, A.; Prodi, L.; Gandolfi, M.T. Handbook of Photochemistry, 3rd ed.; CRC Press; Taylor & Francis: Boca Raton, FL, USA, 2006.

16. Chaves, O.A.; da Silva, V.A.; Sant’Anna, C.M.R.; Ferreira, A.B.B.; Ribeiro, T.A.N.; de Carvalho, M.G.; Cesarin-Sobrinho, D.; Netto-Ferreira, J.C. Binding studies of lophine B with bovine serum albumin (BSA): Combination of spectroscopic and molecular docking techniques. J. Mol. Struct. 2017, 1128, 606–611. [CrossRef]

13. Zhang, W.; Wang, F.; Xiong, X.; Ge, Y.; Liu, Y. Spectroscopic and molecular docking studies on the interaction of dimetridazole with human serum albumin. J. Clin. Chem. Soc. 2013, 58, 1717–1721. [CrossRef]

12. Jokar, S.; Pourjavadi, A.; Adeli, M. Albumin–graphene oxide conjugates; carriers for anticancer drugs. RSC Adv. 2014, 4, 33001. [CrossRef]

34. Da Silveira, C.H.; Chaves, O.A.; Marques, A.C.; Rosa, N.M.O.; Costa, L.A.S.; Iglesias, B.A. Synthesis, photophysics, computational approaches, and biomolecule interactive studies of metalloporphyrins containing pyrenyl units: Influence of the metal center. Eur. J. Inorg. Chem. 2022, 12, e202200075. [CrossRef]

33. Johansson, E.; Nielsen, A.D.; Demuth, H.; Wiberg, C.; Schjedt, C.B.; Huang, T.; Chen, J.; Jensen, S.; Petersen, J.; Thygesen, P. Identification of binding sites on human serum albumin for somapacitan, a long-acting growth hormone derivative. Biochemistry 2020, 59, 1410–1419. [CrossRef] [PubMed]

32. Chaves, O.A.; de Oliveira, C.H.C.S.; Ferreira, R.C.; Pereira, R.P.; de Melos, J.L.R.; Rodrigues-Santos, C.E.; Echevarria, A.; Cesarin-Sobrinho, D. Investigation of interaction between human plasmatic albumin and potential fluorinated anti-trypanosomal drugs. J. Fluor. Chem. 2017, 196, 935–942. [CrossRef] [PubMed]

31. Byadagi, K.; Meti, M.; Nandibewoor, S.; Chimatadar, S. Investigation of binding behaviour of procainamide hydrochloride with human serum albumin using synchronous, 3D fluorescence and circular dichroism. J. Pharm. Anal. 2017, 7, 103–109. [CrossRef] [PubMed]

29. Bertucci, C.; de Simone, A.; Pistolozzi, M.; Rosini, M. Reversible human serum albumin binding of lipocine: A circular dichroism study. Chirality 2011, 23, 827–832. [CrossRef] [PubMed]

28. Chaves, O.A.; de Oliveira, C.H.C.S.; Ferreira, R.C.; Pereira, R.P.; de Melos, J.L.R.; Rodrigues-Santos, C.E.; Echevarria, A.; Cesarin-Sobrinho, D. Probing the interaction between 7-O-β-D-glucopyranosyl-6-(3-methylbut-2-enyl)-5,4-dihydroxylavonol with bovine serum albumin (BSA). J. Photochem. Photobiol. A 2017, 336, 32–41. [CrossRef]

27. Byadagi, K.; Meti, M.; Nandibewoor, S.; Chimatadar, S. Investigation of binding behaviour of procainamide hydrochloride with human serum albumin using synchronous, 3D fluorescence and circular dichroism. J. Pharm. Anal. 2017, 7, 103–109. [CrossRef] [PubMed]

26. Hashempour, S.; Shahabadi, N.; Adewoye, A.; Murphy, B.; Rouse, C.; Salvatore, B.A.; Stratton, C.; Madhavian, E. Binding studies of AICAR and human serum albumin by spectroscopic, theoretical, and computational methodologies. Molecules 2020, 25, 5410. [CrossRef] [PubMed]

25. Karthiga, D.; Chandrasekaran, N.; Mukherjee, N. Spectroscopic studies on the interactions of bovine serum albumin in presence of silver nanorod. J. Mol. Liq. 2017, 232, 251–257. [CrossRef] [PubMed]

24. Caruso, I.P.; Filho, J.M.B.; de Araújo, A.S.; de Souza, F.P.; Fossey, M.A.; Cornélio, M.L. An integrated approach with experimental and computational tools outlining the cooperative binding between 2-phenylchromone and human serum albumin. Food Chem. 2016, 196, 935–942. [CrossRef] [PubMed]

23. Safarnejad, A.; Shaghaghi, M.; Dehghan, G.; Soltani, S. Binding of carvedilol to serum albumins investigated by multi-spectroscopic and molecular modeling methods. J. Lumin. 2016, 176, 149–158. [CrossRef]

22. Amiri, M.; Jankeje, K.; Albani, J.R. Origin of fluorescence lifetimes in human serum protein. Studies on native and denatured protein. J. Fluoresc. 2010, 20, 651–656. [CrossRef]

21. Chaves, O.A.; Cesarin-Sobrinho, D.; Sant’Anna, C.M.R.; de Carvalho, M.G.; Suzart, L.R.; Catunda-Junior, F.E.A.; Netto-Ferreira, J.C.; Ferreira, A.B.B. Probing the interaction between 7-O-β-D-glucopyranosyl-6-(3-methylbut-2-enyl)-5,4-dihydroxylavonol with bovine serum albumin (BSA). J. Photochem. Photobiol. A 2020, 301, 112466. [CrossRef]

20. Chaves, O.A.; Soares, M.A.G.; de Oliveira, M.C.C. Monosaccharides interact weakly with human serum albumin. Insights for the functional perturbations on the binding capacity of albumin. Carbohydr. Res. 2021, 501, 108274. [CrossRef]

19. Chaves, O.A.; Soares, M.A.G.; de Oliveira, M.C.C. Monosaccharides interact weakly with human serum albumin. Insights for the functional perturbations on the binding capacity of albumin. Carbohydr. Res. 2021, 501, 108274. [CrossRef]

18. Sun, H.; Liu, Y.; Li, M.; Han, S.; Yang, X.; Liu, R. Toxic effects of chrysoidine on human serum albumin: Isothermal titration calorimetry and spectroscopic investigations. Luminescence 2016, 31, 335–340. [CrossRef]

17. Montalti, M.; Credi, A.; Prodi, L.; Gandolfi, M.T. Handbook of Photochemistry, 3rd ed.; CRC Press; Taylor & Francis: Boca Raton, FL, USA, 2006.

16. Chaves, O.A.; da Silva, V.A.; Sant’Anna, C.M.R.; Ferreira, A.B.B.; Ribeiro, T.A.N.; de Carvalho, M.G.; Cesarin-Sobrinho, D.; Netto-Ferreira, J.C. Binding studies of lophine B with bovine serum albumin (BSA): Combination of spectroscopic and molecular docking techniques. J. Mol. Struct. 2017, 1128, 606–611. [CrossRef]

13. Zhang, W.; Wang, F.; Xiong, X.; Ge, Y.; Liu, Y. Spectroscopic and molecular docking studies on the interaction of dimetridazole with human serum albumin. J. Clin. Chem. Soc. 2013, 58, 1717–1721. [CrossRef]

12. Jokar, S.; Pourjavadi, A.; Adeli, M. Albumin–graphene oxide conjugates; carriers for anticancer drugs. RSC Adv. 2014, 4, 33001. [CrossRef]

11. Sun, H.; Liu, Y.; Li, M.; Han, S.; Yang, X.; Liu, R. Toxic effects of chrysoidine on human serum albumin: Isothermal titration calorimetry and spectroscopic investigations. Luminescence 2016, 31, 335–340. [CrossRef]
37. Cohen, S.; Margalit, R. Binding of porphyrin to human serum albumin. Structure–activity relationships. *Biochem. J.* 1990, 270, 325–330. [CrossRef]

38. Chaves, O.A.; Menezes, L.B.; Iglesias, B.A. Multiple spectroscopic and theoretical investigation of meso-tetra-(4-pyridyl)porphyrin ruthenium(II) complexes in HSA binding studies. Effect of Zn(II) in protein binding. *J. Mol. Liq.* 2019, 294, 111581. [CrossRef]

39. Ding, Y.; Lin, B.; Huie, C.W. Binding studies of porphyrins to human serum albumin using affinity capillary electrophoresis. *Electrophoresis* 2001, 22, 2210–2216. [CrossRef]

40. Kubát, P.; Lang, K.; Anzenbacher, P. Modulation of porphyrin binding to serum albumin by pH. *Biochim. Biophys. Acta (BBA)-Gen. Subj.* 2004, 1670, 40–48. [CrossRef]

41. Naveenraj, S.; Anandan, S. Binding of serum albumins with bioactive substances—Nanoparticles to drugs. *J. Photochem. Photobiol. C* 2013, 14, 53–71. [CrossRef]

42. Ross, P.D.; Subramanian, S. Thermodynamics of protein association reactions: Forces contributing to stability. *Biochemistry* 1981, 20, 3096–3102. [CrossRef]

43. Chaves, O.A.; Jesus, C.S.H.; Cruz, P.F.; Sant’Anna, C.M.R.; Brito, R.M.M.; Serpa, C. Evaluation by fluorescence, STD-NMR, docking and semi-empirical calculations of the o-NBA photo-acid interaction with BSA. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* 2016, 169, 175–181. [CrossRef]

44. Matei, I.; Hillebrand, M. Interaction of kaempferol with human serum albumin: A fluorescence and circular dichroism study. *J. Pharm. Biomed. Anal.* 2010, 51, 768–773. [CrossRef]

45. Chaves, O.A.; Amorim, A.P.O.; Castro, L.H.E.; de Sant’Anna, C.M.R.; de Oliveira, M.C.C.; Cesarin-Sobrinho, D.; Netto-Ferreira, J.C.; Ferreira, A.B.B. Fluorescence and docking studies of the interaction between human serum albumin and pheophytin. *Molecules* 2015, 20, 19526–19539. [CrossRef] [PubMed]

46. Zaidi, N.; Ajmal, M.R.; Rabbani, G.; Ahmad, E.; Khan, R.H. A comprehensive insight into binding of hippuric acid to human serum albumin: A study to uncover its impaired elimination through hemodialysis. *PLoS ONE* 2013, 8, e71422. [CrossRef] [PubMed]

47. Grossweiner, L.I. A note on the analysis of ligand binding by the double-logarithmic plot. *J. Photochem. Photobiol. B* 2000, 58, 175–177. [CrossRef]

48. Hein, K.L.; Kragh-Hansen, U.; Morth, J.P.; Jeppesen, M.D.; Otzen, D.; Moller, J.V.; Nissen, P. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. *J. Struct. Biol.* 2010, 171, 353–360. [CrossRef]